HighMark Wealth Management’s Aldeyra Therapeutics ALDX Stock Holding History

HighMark Wealth Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$261	Hold	155	–	–	﹤0.01%	526
2025 Q4	$802	Hold	155	–	–	﹤0.01%	520
2025 Q3	$809	Hold	155	–	–	﹤0.01%	537
2025 Q2	$594	Hold	155	–	–	﹤0.01%	550
2025 Q1	$891	Hold	155	–	–	﹤0.01%	496
2024 Q4	$773	Hold	155	–	–	﹤0.01%	506
2024 Q3	$835	Hold	155	–	–	﹤0.01%	524
2024 Q2	$513	Hold	155	–	–	﹤0.01%	535
2024 Q1	$507	Hold	155	–	–	﹤0.01%	525
2023 Q4	$544	Hold	155	–	–	﹤0.01%	533
2023 Q3	$1.03K	Hold	155	–	–	﹤0.01%	503
2023 Q2	$1.3K	Hold	155	–	–	﹤0.01%	489
2023 Q1	$1.54K	Hold	155	–	–	﹤0.01%	522
2022 Q4	$1.08K	Hold	155	–	–	﹤0.01%	468
2022 Q3	$1K	Sell	155 -610	-80%	-$3.66K	﹤0.01%	455
2022 Q2	$3K	Sell	765 -2,000	-72%	-$6.88K	﹤0.01%	388
2022 Q1	$12K	Sell	2,765 -350	-11%	-$1.39K	0.01%	234
2021 Q4	$12K	Sell	3,115 -1,442	-32%	-$11K	0.01%	230
2021 Q3	$40K	Buy	4,557 +197	+5%	+$1.81K	0.03%	129
2021 Q2	$49K	Buy	4,360 +3,501	+408%	+$42.1K	0.04%	115
2021 Q1	$10K	Buy	+859	New	+$9.89K	0.01%	229

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HighMark Wealth Management's ALDX Position: Q1 2026 in Review

HighMark Wealth Management held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 155 shares worth $261. The position accounts for ﹤0.01% of the portfolio, ranked #526.

HighMark Wealth Management first reported a position in ALDX in Q1 2021 and has held it in 21 quarters since. The position peaked at $49K in Q2 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

HighMark Wealth Management held 155 shares of Aldeyra Therapeutics worth $261 as of Q1 2026.
HighMark Wealth Management left its Aldeyra Therapeutics share count unchanged in Q1 2026.
Aldeyra Therapeutics made up ﹤0.01% of HighMark Wealth Management's portfolio in Q1 2026, its #526 holding.
HighMark Wealth Management first reported a position in Aldeyra Therapeutics in Q1 2021 and has held it in 21 quarters since.
HighMark Wealth Management's Aldeyra Therapeutics position peaked at $49K in Q2 2021.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.